870 Martin Luther King Jr. Blvd.
Chapel Hill, NC 27514
Welcome to Scrip
Create an account to read this article
Already a subscriber?
NanoCor Therapeutics Inc.
With rights to a novel gene that it believes will help protect and repair damaged heart tissue and an adeno-associated virus (AAV) gene therapy delivery system, NanoCor Therapeutics is currently developing preclinical data to support the use of its gene therapy to treat chronic heart failure patients awaiting a heart transplant.
More from Cell Therapies
• By
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
• By
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
• By
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
• By
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
More from Advanced Therapies
• By
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
• By
Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.
• By
The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.